KLK3 and posterior cortical atrophy: The risk classification and treatment strategies for PCa are determined according to clinical parameters such as prostate specific antigen (PSA), PSA density (PSAD), age, radiologic findings such as magnetic resonance imaging (MRI), and prostate biopsy findings4.